查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1771645

創傷性腦損傷生物標記市場規模、佔有率、趨勢分析報告：按類型、樣本類型、應用、最終用途、地區和細分市場預測，2025-2033

Traumatic Brain Injury Biomarkers Market Size, Share & Trends Analysis Report By Type (Protein Biomarkers, Genetic Biomarkers), By Sample Type, By Application, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

創傷性腦損傷生物標記市場摘要

2024 年全球創傷性腦損傷生物標記市場規模估計為 10.4 億美元，預計到 2033 年將達到 47.3 億美元，2025 年至 2033 年的複合年成長率為 18.84%。由於創傷性腦損傷發病率的增加、對快速照護現場的需求不斷成長以及向個人化醫療和遠端醫療的轉變，市場面臨顯著成長。

創傷性腦損傷 (TBI) 是長期殘疾和死亡的主要原因之一，也是美國的健康問題。根據美國疾病管制與預防中心的數據，到 2024 年，美國每年將有 280 萬人被診斷出患有腦損傷，超過 5.6 萬人將死於 TBI。雖然任何人都有可能患上 TBI，但男性患 TBI 的可能性大約是女性的 1.5 倍，死於 TBI 的可能性則是女性的三倍。

交通事故、運動傷害、老年人跌倒以及軍隊戰鬥傷害等趨勢的增加是造成這一趨勢的主要原因。每年因創傷性腦損傷 (TBI) 致殘的人數是脊髓損傷、多發性硬化症、愛滋病毒/愛滋病和乳癌致殘人數總和的六倍。下方圓餅圖顯示了導致 TBI 的主要原因。

創傷性腦損傷病例的激增刺激了對可靠的早期診斷工具（如有助於及時發現和治療的生物標記）的需求，最終推動市場成長。

65歲及以上族群最有可能因創傷性腦損傷 (TBI) 住院或死亡，其中跌倒是主要原因。在所有年齡層中，男性比女性更容易罹患嚴重TBI，不僅住院的可能性更高，而且死於TBI的可能性也幾乎是女性的三倍。

因此，對快速、便攜的 TBI照護現場工具的需求日益成長，尤其是在事故現場、體育場、軍事戰場等院前環境中。基於生物標記的快速且準確檢測結果將有助於及時做出臨床決策、改善患者預後並降低醫療成本。

目前正在進行研究，探討生物標記是否可用於臨床試驗，以輔助開發創傷性腦損傷 (TBI) 的新治療方法。這些生物標記可以改善對 TBI 嚴重程度的診斷和評估，並有助於篩選合適的患者參與藥物試驗。美國食品藥物管理局 (FDA) 於 2022 年 9 月報告了一項此類研究，該研究重點關注識別和檢驗能夠準確檢測創傷性腦損傷 (TBI) 並評估其嚴重程度的診斷性生物標記，以改善早期診斷和患者管理。該研究成功鑑定出與 TBI 的存在和嚴重程度密切相關的潛在生物標記物，為改進診斷工具奠定了基礎，並有助於在未來的臨床試驗中更準確地選擇患者。

隨著個人化醫療日益受到重視，對基於生物標記的診斷方法的需求也日益成長，這些診斷方法可根據患者的個別特徵和損傷嚴重程度進行客製化。生物標記使臨床醫生能夠客製化治療策略，改善療效並減少副作用。生物標記識別檢測領域的創新正在開發中，重點是個人化醫療。

例如，2024年5月，生物梅里埃的VIDAS TBI檢測獲得美國FDA 510(k)批准，這是一種基於血清的檢測方法，旨在輔助評估輕度創傷性腦損傷（mTBI）患者，包括腦震盪。此檢測有助於發現急性顱內病變（ICL）可能性較低的患者，並有助於減少不必要的頭部CT掃描次數。 VIDAS TBI還能幫助醫療保健提供者根據個別患者的需求做出更快、更明智的決策。因此，這種方法的結合有助於持續監測和及時干預，透過將生物標記檢測整合到個人化治療方法中來支持市場成長。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 創傷性腦損傷生物標記市場變數、趨勢和範圍

  • 市場展望
    • 母市場展望
    • 相關/輔助市場展望。
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 創傷性腦損傷生物標記市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章創傷性腦損傷生物標記市場：類型估計和趨勢分析

  • 2024 年及 2033 年各類型市場佔有率
  • 細分儀表板
  • 創傷性腦損傷生物標記市場：類型變異分析
  • 2021 年至 2033 年創傷性腦損傷生物標記市場規模及趨勢分析
  • 2021-2033年創傷性腦損傷生物標記市場收益估計與預測
  • 蛋白質生物標記
  • 基因生物標記
  • 代謝體學學生物標記

第5章創傷性腦損傷生物標記市場：樣本類型估計和趨勢分析

  • 樣本類型市場佔有率，2024 年和 2033 年
  • 細分儀表板
  • 全球創傷性腦損傷生物標記市場（按樣本類型）展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 血液類
  • 基於腦脊髓液（CSF）
  • 尿基

第6章創傷性腦損傷生物標記市場：應用評估與趨勢分析

  • 2024 年和 2033 年應用市場佔有率
  • 細分儀表板
  • 全球創傷性腦損傷生物標記市場應用展望
  • 2021年至2033年市場規模、預測與趨勢分析
  • 診斷
  • 預後
  • 監測治療反應

7. 創傷性腦損傷生物標記市場：最終用途預估與趨勢分析

  • 2024年及2033年最終用途市場佔有率
  • 細分儀表板
  • 全球創傷性腦損傷生物標記市場展望（按最終用途）
  • 2021年至2033年市場規模、預測與趨勢分析
  • 醫院和診所
  • 診斷實驗室
  • 研究所

8. 創傷性腦損傷生物標記市場：區域估計和趨勢分析

  • 2024 年及 2033 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 市場規模、預測趨勢分析，2021-2033年：
  • 北美洲
    • 北美：SWOT分析
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 歐洲：SWOT分析
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 亞太地區：SWOT分析
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 拉丁美洲：SWOT分析
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 中東和非洲：SWOT分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • Key customers
    • Key company market share analysis, 2024
Product Code: GVR-4-68040-624-1

Traumatic Brain Injury Biomarkers Market Summary

The global traumatic brain injury biomarkers market size was estimated at USD 1.04 billion in 2024 and is projected to reach USD 4.73 billion by 2033, growing at a CAGR of 18.84% from 2025 to 2033. The market is facing significant growth driven by rising incidents of traumatic brain injuries, growing demand for rapid and point-of-care diagnostics, and a shift towards personalized medicine and telehealth.

Traumatic brain injury (TBI) remains a major global health concern, ranking among the leading causes of long-term disability and mortality. According to the Centers for Disease Control and Prevention, in 2024, 2.8 million people in America were diagnosed with brain injury every year, and more than 56,000 people died as a result of TBI. Although everyone is at risk of sustaining a traumatic brain injury (TBI), males are approximately 1.5 times more likely than females to experience a TBI and have a mortality rate that is three times higher.

Factors such as increasing road traffic accidents, sports-related injuries, falls among the elderly, and military combat injuries contribute significantly to this trend. Each year, traumatic brain injury (TBI) results in disability for six times more individuals than spinal cord injuries, multiple sclerosis, HIV/AIDS, and breast cancer combined. The pie chart below illustrates leading causes of TBI:

This surge in TBI cases fuels demand for reliable, early diagnostic tools like biomarkers that can aid in timely detection and treatment, ultimately driving market growth.

Individuals aged 65 and above are the most vulnerable to hospitalization and death caused by traumatic brain injury (TBI), with falls being the leading cause. Across all age groups, men experience higher rates of severe TBI compared to women, and they are not only more frequently hospitalized but also face nearly triple the risk of death from TBI.

Thus, there is a growing need for rapid, portable, and point-of-care diagnostic tools for TBI, particularly in pre-hospital environments such as accident scenes, sports fields, and military battlefields. Biomarker-based tests that provide quick and accurate results enable timely clinical decisions, improving patient outcomes and reducing healthcare costs.

Studies are being conducted to investigate whether biomarkers can be used in clinical trials to support the development of new treatments for traumatic brain injury (TBI). These biomarkers could improve the diagnosis and evaluation of TBI severity, facilitating the selection of suitable patients for participation in drug trials. One such study reported by the USFDA, conducted in September 2022, focused on identifying and validating diagnostic biomarkers that accurately detected traumatic brain injury (TBI) and assessed the severity to improve early diagnosis and patient management. The study successfully identified potential biomarkers that demonstrated a strong correlation with TBI presence and severity, laying the groundwork for improved diagnostic tools and enabling more precise patient selection in future clinical trials.

The increasing focus on personalized medicine is driving demand for biomarker-based diagnostics tailored to individual patient profiles and severity of injury. Biomarkers enable clinicians to customize treatment strategies, improving outcomes and reducing adverse effects. Innovations in biomarker identification tests are in development with a focus on personalized medicine.

For instance, in May 2024, bioMerieux received U.S. FDA 510(k) clearance for VIDAS TBI, a serum-based test designed to assist in evaluating patients with mild traumatic brain injury (mTBI), including concussions. This test assists in detecting patients who are unlikely to have acute intracranial lesions (ICL), which helps decrease the number of unnecessary head CT scans. VIDAS TBI also enables healthcare providers to make faster, better-informed decisions tailored to individual patient needs. Thus, inculcating such approaches promotes continuous monitoring and timely intervention, supporting market growth by integrating biomarker testing into personalized therapeutic approaches.

Global Traumatic Brain Injury Biomarkers Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global traumatic brain injury biomarkers market report based on type, sample type, application, end use, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Protein Biomarkers
  • Genetic Biomarkers
  • Metabolomic Biomarkers
  • Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Blood-based
  • Cerebrospinal fluid (CSF)-based
  • Urine-based
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Diagnosis
  • Prognosis
  • Monitoring treatment response
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Research Institutes
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Sample Type
    • 1.2.3. Application
    • 1.2.4. End use
    • 1.2.5. Regional scope
    • 1.2.6. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Sample type outlook
    • 2.2.3. Application outlook
    • 2.2.4. End use outlook
    • 2.2.5. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Traumatic Brain Injury Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Traumatic Brain Injury Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Traumatic Brain Injury Biomarkers Market: Type Estimates & Trend Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Traumatic Brain Injury Biomarkers Market: Type Movement Analysis
  • 4.4. Traumatic Brain Injury Biomarkers Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.5. Traumatic Brain Injury Biomarkers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Protein biomarkers
    • 4.6.1. Protein biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.7. Genetic biomarkers
    • 4.7.1. Genetic biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.8. Metabolomic biomarkers
    • 4.8.1. Metabolomic biomarkers Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Traumatic Brain Injury Biomarkers Market: Sample type Estimates & Trend Analysis

  • 5.1. Sample type Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Traumatic Brain Injury Biomarkers Market by Sample type Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.5. Blood-based
    • 5.5.1. Blood-based Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Cerebrospinal fluid (CSF)-based
    • 5.6.1. Cerebrospinal fluid (CSF)-based Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Urine-based
    • 5.7.1. Urine-based Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Traumatic Brain Injury Biomarkers Market: Application Estimates & Trend Analysis

  • 6.1. Application Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Traumatic Brain Injury Biomarkers Market by Application Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.5. Diagnosis
    • 6.5.1. Diagnosis Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Prognosis
    • 6.6.1. Prognosis Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Monitoring treatment response
    • 6.7.1. Monitoring treatment response Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Traumatic Brain Injury Biomarkers Market: End use Estimates & Trend Analysis

  • 7.1. End use Market Share, 2024 & 2033
  • 7.2. Segment Dashboard
  • 7.3. Global Traumatic Brain Injury Biomarkers Market by End use Outlook
  • 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 7.5. Hospitals & Clinics
    • 7.5.1. Hospitals & Clinics Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Diagnostic Laboratories
    • 7.6.1. Diagnostic Laboratories Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Research Institutes
    • 7.7.1. Research Institutes Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. Traumatic Brain Injury Biomarkers Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Global Regional Market Snapshot
  • 8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 8.5. North America
    • 8.5.1. North America: SWOT Analysis
    • 8.5.2. U.S.
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework/Reimbursement
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.3. Canada
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework/Reimbursement
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.4. Mexico
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework/Reimbursement
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6. Europe
    • 8.6.1. Europe: SWOT Analysis
    • 8.6.2. UK
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework/Reimbursement
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.3. Germany
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework/Reimbursement
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.4. France
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework/Reimbursement
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.5. Italy
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework/Reimbursement
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.6. Spain
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework/Reimbursement
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.7. Norway
      • 8.6.7.1. Key country dynamics
      • 8.6.7.2. Regulatory framework/Reimbursement
      • 8.6.7.3. Competitive scenario
      • 8.6.7.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.8. Sweden
      • 8.6.8.1. Key country dynamics
      • 8.6.8.2. Regulatory framework/Reimbursement
      • 8.6.8.3. Competitive scenario
      • 8.6.8.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.9. Denmark
      • 8.6.9.1. Key country dynamics
      • 8.6.9.2. Regulatory framework/Reimbursement
      • 8.6.9.3. Competitive scenario
      • 8.6.9.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7. Asia Pacific
    • 8.7.1. Asia Pacific: SWOT Analysis
    • 8.7.2. Japan
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework/Reimbursement
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.3. China
      • 8.7.3.1. Key country dynamics
      • 8.7.3.2. Regulatory framework/Reimbursement
      • 8.7.3.3. Competitive scenario
      • 8.7.3.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.4. India
      • 8.7.4.1. Key country dynamics
      • 8.7.4.2. Regulatory framework/Reimbursement
      • 8.7.4.3. Competitive scenario
      • 8.7.4.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.5. Australia
      • 8.7.5.1. Key country dynamics
      • 8.7.5.2. Regulatory framework/Reimbursement
      • 8.7.5.3. Competitive scenario
      • 8.7.5.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.6. South Korea
      • 8.7.6.1. Key country dynamics
      • 8.7.6.2. Regulatory framework/Reimbursement
      • 8.7.6.3. Competitive scenario
      • 8.7.6.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.7. Thailand
      • 8.7.7.1. Key country dynamics
      • 8.7.7.2. Regulatory framework/Reimbursement
      • 8.7.7.3. Competitive scenario
      • 8.7.7.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.8. Latin America
    • 8.8.1. Latin America: SWOT Analysis
    • 8.8.2. Brazil
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework/Reimbursement
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.3. Argentina
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework/Reimbursement
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.9. MEA
    • 8.9.1. MEA: SWOT Analysis
    • 8.9.2. South Africa
      • 8.9.2.1. Key country dynamics
      • 8.9.2.2. Regulatory framework/Reimbursement
      • 8.9.2.3. Competitive scenario
      • 8.9.2.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.3. Saudi Arabia
      • 8.9.3.1. Key country dynamics
      • 8.9.3.2. Regulatory framework/Reimbursement
      • 8.9.3.3. Competitive scenario
      • 8.9.3.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.4. UAE
      • 8.9.4.1. Key country dynamics
      • 8.9.4.2. Regulatory framework/Reimbursement
      • 8.9.4.3. Competitive scenario
      • 8.9.4.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.9.5. Kuwait
      • 8.9.5.1. Key country dynamics
      • 8.9.5.2. Regulatory framework
      • 8.9.5.3. Competitive scenario
      • 8.9.5.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 9.2. Company/Competition Categorization
  • 9.3. Vendor Landscape
    • 9.3.1. List of key distributors and channel partners
    • 9.3.2. Key customers
    • 9.3.3. Key company market share analysis, 2024
      • 9.3.3.1. Quanterix.
        • 9.3.3.1.1. Company overview
        • 9.3.3.1.2. Financial performance
        • 9.3.3.1.3. Services benchmarking
        • 9.3.3.1.4. Strategic initiatives
      • 9.3.3.2. Banyan Biomarkers, Inc.
        • 9.3.3.2.1. Company overview
        • 9.3.3.2.2. Financial performance
        • 9.3.3.2.3. Services benchmarking
        • 9.3.3.2.4. Strategic initiatives
      • 9.3.3.3. Abbott
        • 9.3.3.3.1. Company overview
        • 9.3.3.3.2. Financial performance
        • 9.3.3.3.3. Services benchmarking
        • 9.3.3.3.4. Strategic initiatives
      • 9.3.3.4. Siemens Healthineers AG
        • 9.3.3.4.1. Company overview
        • 9.3.3.4.2. Financial performance
        • 9.3.3.4.3. Services benchmarking
        • 9.3.3.4.4. Strategic initiatives
      • 9.3.3.5. GE Healthcare.
        • 9.3.3.5.1. Company overview
        • 9.3.3.5.2. Financial performance
        • 9.3.3.5.3. Services benchmarking
        • 9.3.3.5.4. Strategic initiatives
      • 9.3.3.6. Koninklijke Philips N.V.
        • 9.3.3.6.1. Company overview
        • 9.3.3.6.2. Financial performance
        • 9.3.3.6.3. Services benchmarking
        • 9.3.3.6.4. Strategic initiatives
      • 9.3.3.7. Fujirebio
        • 9.3.3.7.1. Company overview
        • 9.3.3.7.2. Financial performance
        • 9.3.3.7.3. Services benchmarking
        • 9.3.3.7.4. Strategic initiatives
      • 9.3.3.8. Thermo Fisher Scientific Inc.
        • 9.3.3.8.1. Company overview
        • 9.3.3.8.2. Financial performance
        • 9.3.3.8.3. Services benchmarking
        • 9.3.3.8.4. Strategic initiatives
      • 9.3.3.9. Randox Laboratories Ltd.
        • 9.3.3.9.1. Company overview
        • 9.3.3.9.2. Financial performance
        • 9.3.3.9.3. Services benchmarking
        • 9.3.3.9.4. Strategic initiatives
      • 9.3.3.10. Immunarray.
        • 9.3.3.10.1. Company overview
        • 9.3.3.10.2. Financial performance
        • 9.3.3.10.3. Services benchmarking
        • 9.3.3.10.4. Strategic initiatives
      • 9.3.3.11. Oculogica
        • 9.3.3.11.1. Company overview
        • 9.3.3.11.2. Financial performance
        • 9.3.3.11.3. Services benchmarking
        • 9.3.3.11.4. Strategic initiatives
      • 9.3.3.12. NeuroTrauma Sciences, LLC
        • 9.3.3.12.1. Company overview
        • 9.3.3.12.2. Financial performance
        • 9.3.3.12.3. Services benchmarking
        • 9.3.3.12.4. Strategic initiatives
      • 9.3.3.13. BRAINBox Solutions, Inc.
        • 9.3.3.13.1. Company overview
        • 9.3.3.13.2. Financial performance
        • 9.3.3.13.3. Services benchmarking
        • 9.3.3.13.4. Strategic initiatives
      • 9.3.3.14. BioMerieux
        • 9.3.3.14.1. Company overview
        • 9.3.3.14.2. Financial performance
        • 9.3.3.14.3. Services benchmarking
        • 9.3.3.14.4. Strategic initiatives
      • 9.3.3.15. Myriad Genetics, Inc.
        • 9.3.3.15.1. Company overview
        • 9.3.3.15.2. Financial performance
        • 9.3.3.15.3. Services benchmarking
        • 9.3.3.15.4. Strategic initiatives
      • 9.3.3.16. QIAGEN N.V.
        • 9.3.3.16.1. Company overview
        • 9.3.3.16.2. Financial performance
        • 9.3.3.16.3. Services benchmarking
        • 9.3.3.16.4. Strategic initiatives
      • 9.3.3.17. F. Hoffmann-La Roche Ltd
        • 9.3.3.17.1. Company overview
        • 9.3.3.17.2. Financial performance
        • 9.3.3.17.3. Services benchmarking
        • 9.3.3.17.4. Strategic initiatives
      • 9.3.3.18. Abcam Limited
        • 9.3.3.18.1. Company overview
        • 9.3.3.18.2. Financial performance
        • 9.3.3.18.3. Services benchmarking
        • 9.3.3.18.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America Traumatic Brain Injury biomarkers market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 4 North America Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 5 North America Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 6 North America Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 7 U.S Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 8 U.S Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 9 U.S Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 10 U.S Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 11 Canada Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 12 Canada Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 13 Canada Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 14 Canada Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 15 Mexico Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 16 Mexico Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 17 Mexico Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 18 Mexico Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 20 Europe Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 21 Europe Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 22 Europe Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 23 UK Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 24 UK Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 25 UK Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 26 UK Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 27 Germany Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 28 Germany Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 29 Germany Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 30 Germany Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 31 France Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 32 France Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 33 France Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 34 France Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Italy Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 36 Italy Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 37 Italy Traumatic Brain Injury biomarkers market, application, 2021 - 2033 (USD Million)
  • Table 38 Italy Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 39 Spain Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 40 Spain Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 41 Spain Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 42 Spain Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 43 Denmark Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 44 Denmark Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 45 Denmark Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 46 Denmark Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Sweden Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 48 Sweden Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 49 Sweden Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 50 Sweden Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 51 Norway Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 52 Norway Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 53 Norway Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 54 Norway Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 55 Asia Pacific Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 56 Asia Pacific Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 57 Asia Pacific Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 58 Asia Pacific Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 59 Japan Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 60 Japan Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 61 Japan Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 62 Japan Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 63 China Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 64 China Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 65 China Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 66 China Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 67 India Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 68 India Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 69 India Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 70 India Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 71 Australia Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 72 Australia Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 73 Australia Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 74 Australia Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 75 South Korea Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 76 South Korea Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 77 South Korea Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 78 South Korea Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Thailand Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 80 Thailand Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 81 Thailand Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 82 Thailand Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 83 Latin America Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 84 Latin America Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 85 Latin America Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 86 Latin America Traumatic Brain Injury biomarkers market, by end use 2021 - 2033 (USD Million)
  • Table 87 Brazil Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 88 Brazil Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 89 Brazil Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 90 Brazil Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Argentina Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 92 Argentina Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 93 Argentina Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 94 Argentina Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 95 MEA Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 96 MEA Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 97 MEA Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 98 MEA Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 99 South Africa Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 100 South Africa Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 101 South Africa Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 102 South Africa Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 103 Saudi Arabia Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 104 Saudi Arabia Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 105 Saudi Arabia Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 106 Saudi Arabia Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 107 UAE Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 108 UAE Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 109 UAE Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 110 UAE Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)
  • Table 111 Kuwait Traumatic Brain Injury biomarkers market, by type, 2021 - 2033 (USD Million)
  • Table 112 Kuwait Traumatic Brain Injury biomarkers market, by sample type, 2021 - 2033 (USD Million)
  • Table 113 Kuwait Traumatic Brain Injury biomarkers market, by application, 2021 - 2033 (USD Million)
  • Table 114 Kuwait Traumatic Brain Injury biomarkers market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Traumatic Brain Injury biomarkers market: market outlook
  • Fig. 14 Traumatic Brain Injury biomarkers competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Traumatic Brain Injury Biomarkers market driver impact
  • Fig. 20 Traumatic Brain Injury Biomarkers market restraint impact
  • Fig. 21 Traumatic Brain Injury Biomarkers market strategic initiatives analysis
  • Fig. 22 Traumatic Brain Injury Biomarkers market: Type movement analysis
  • Fig. 23 Traumatic Brain Injury Biomarkers market: Type outlook and key takeaways
  • Fig. 24 Protein biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 25 Genetic biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 26 Metabolomic biomarkers market estimates and forecasts, 2021 - 2033
  • Fig. 27 Traumatic Brain Injury Biomarkers Market: Sample type movement analysis
  • Fig. 28 Traumatic Brain Injury Biomarkers market: Sample type outlook and key takeaways
  • Fig. 29 Blood-based market estimates and forecasts, 2021 - 2033
  • Fig. 30 Cerebrospinal fluid (CSF)-based market estimates and forecasts, 2021 - 2033
  • Fig. 31 Urine-based market estimates and forecasts, 2021 - 2033
  • Fig. 32 Traumatic Brain Injury Biomarkers Market: Application movement analysis
  • Fig. 33 Traumatic Brain Injury Biomarkers market: Application outlook and key takeaways
  • Fig. 34 Diagnosis market estimates and forecasts, 2021 - 2033
  • Fig. 35 Prognosis market estimates and forecasts, 2021 - 2033
  • Fig. 36 Monitoring treatment response market estimates and forecasts, 2021 - 2033
  • Fig. 37 Traumatic Brain Injury Biomarkers Market: End use movement analysis
  • Fig. 38 Traumatic Brain Injury Biomarkers market: End use outlook and key takeaways
  • Fig. 39 Hospitals & Clinics market estimates and forecasts, 2021 - 2033
  • Fig. 40 Diagnostic Laboratories market estimates and forecasts, 2021 - 2033
  • Fig. 41 Research Institutes market estimates and forecasts, 2021 - 2033
  • Fig. 42 Global Traumatic Brain Injury Biomarkers market: Regional movement analysis
  • Fig. 43 Global Traumatic Brain Injury Biomarkers market: Regional outlook and key takeaways
  • Fig. 44 Global Traumatic Brain Injury Biomarkers market share and leading players
  • Fig. 45 North America market share and leading players
  • Fig. 46 Europe market share and leading players
  • Fig. 47 Asia Pacific market share and leading players
  • Fig. 48 Latin America market share and leading players
  • Fig. 49 Middle East & Africa market share and leading players
  • Fig. 50 North America
  • Fig. 51 North America market estimates and forecasts, 2021 - 2033
  • Fig. 52 U S
  • Fig. 53 U S market estimates and forecasts, 2021 - 2033
  • Fig. 54 Canada
  • Fig. 55 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 56 Mexico
  • Fig. 57 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 58 Europe
  • Fig. 59 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 60 UK
  • Fig. 61 UK market estimates and forecasts, 2021 - 2033
  • Fig. 62 Germany
  • Fig. 63 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 64 France
  • Fig. 65 France market estimates and forecasts, 2021 - 2033
  • Fig. 66 Italy
  • Fig. 67 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 68 Spain
  • Fig. 69 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 70 Denmark
  • Fig. 71 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 72 Sweden
  • Fig. 73 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 74 Norway
  • Fig. 75 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 76 Asia Pacific
  • Fig. 77 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 78 China
  • Fig. 79 China market estimates and forecasts, 2021 - 2033
  • Fig. 80 Japan
  • Fig. 81 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 82 India
  • Fig. 83 India market estimates and forecasts, 2021 - 2033
  • Fig. 84 Thailand
  • Fig. 85 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 86 South Korea
  • Fig. 87 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 88 Australia
  • Fig. 89 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 90 Latin America
  • Fig. 91 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 92 Brazil
  • Fig. 93 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 94 Argentina
  • Fig. 95 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 96 Middle East and Africa
  • Fig. 97 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 98 South Africa
  • Fig. 99 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 100 Saudi Arabia
  • Fig. 101 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 102 UAE
  • Fig. 103 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 104 Kuwait
  • Fig. 105 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 106 Market share of key market players- Traumatic Brain Injury Biomarkers market